Effects of lithium therapy on Na +-K +-ATPase activity and lipid peroxidation in bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 56-61

  Banerjee, Ushasi ^a   Dasgupta, Anindya ^a   Rout, Jayanta Kumar ^a,b   Singh, Om Prakash ^a  

^a BURDWAN MEDICAL COLLEGE AND HOSPITAL   (India)

^b R G KAR MEDICAL COLLEGE   (India)

Author keywords

Bipolar disorder; Lipid peroxidation; Lithium; Na + K + ATPase activity

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); LITHIUM SALT; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE;

ADULT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; ENZYME ACTIVATION; FEMALE; HUMANS; LIPID PEROXIDATION; LITHIUM; MALE; MIDDLE AGED; OXIDATIVE STRESS; SODIUM-POTASSIUM-EXCHANGING ATPASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84857789619     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.006     Document Type: Article

References (52)

1. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41:523-529.
2. Anon. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-50.
3. Anon. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR 2004, American Psychiatric Association.
4. Bech P., Kirkegaard C., Bock E., Johannesen M., Rafaelsen O.J. Hormones, electrolytes, and cerebrospinal fluid proteins in manic-melancholic patients. Neuropsychobiology 1978, 4:99-112.
5. Calabrese V., Scapagnini G., Giuffrida Stella A.M., Bates T.E., Clark J.B. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001, 26:739-764.
6. Carli M., Morissette M., Hebert C., Di Paolo T., Reader T.A. Effects of a chronic lithium treatment on central dopamine neurotransporters. Biochem Pharmacol 1997, 54:391-397.
7. Chakraborty S., Singh O.P., Dasgupta A., Mandal N., Nath Das H. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:363-366.
8. Connolly K.R., Thase M.E. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 2011, 13(4).
9. Coyle J.T., Manji H.K. Getting balance: drugs for bipolar disorder share target. Nat Med 2002, 8:557-558.
10. Dahle L.K., Hill E.G., Holman R.T. The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 1962, 98:253-261.
11. Daly S.E., Lane L.K., Blostein R. Functional consequences of amino-terminal diversity of the catalytic subunit of the Na, K-ATPase. J Biol Chem 1994, 269:23944-23948.
12. +, K(+)-ATPase activity is reduced in hippocampus of rats submitted to an experimental model of depression: effect of chronic lithium treatment and possible involvement in learning deficits. Neurobiol Learn Mem 2005, 84:102-110.
13. de Vasconcellos A.P., Nieto F.B., Crema L.M., Diehl L.A., de Almeida L.M., Prediger M.E., et al. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res 2006, 31:1141-1151.
14. Ellis D.Z., Rabe J., Sweadner K.J. Global loss of Na, K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2003, 23:43-51.
15. El-Mallakh R.S., El-Masri M.A., Huff M.O., Li X.P., Decker S., Levy R.S. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 2003, 5:362-365.
16. Fan T.W., Yuan P., Lane A.N., Higashi R.M., Wang Y., Hamidi A.B., et al. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics 2010, 6:165-179.
17. + pump regulation. Circ Res 2009, 105:185-193.
18. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
19. Frey B.N., Andreazza A.C., Kunz M., Gomes F.A., Quevedo J., Salvador M., et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:283-285.
20. +K)-ATPase. Biochem Pharmacol 1981, 30:25-30.
21. Hesketh J.E., Glen A.I., Reading H.W. Membrane ATPase activities in depressive illness. J Neurochem 1977, 28:1401-1402.
22. Hoang U., Stewart R., Goldacre M.J. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 2011, 343:d5422.
23. Huang X., Lei Z., Li X.P., El-Mallakh R.S. Response of sodium pump to ouabain challenge in human glioblastoma cells in culture. World J Biol Psychiatry 2009, 10:884-892.
24. Johnston B.B., Naylor G.J., Dick E.G., Hopwood S.E., Dick D.A. Prediction of clinical course of bipolar manic depressive illness treated with lithium. Psychol Med 1980, 10:329-334.
25. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999, 4:117-128.
26. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000, 2:180-190.
27. Kelly T., Kafitz K.W., Roderigo C., Rose C.R. Ammonium-evoked alterations in intracellular sodium and pH reduce glial glutamate transport activity. Glia 2009, 57:921-934.
28. Kielczykowska M., Pasternak K., Boguszewska A., Musik I. The influence of chosen metals administration in drinking water on magnesium balance in rats. Ann Univ Mariae Curie Sklodowska Med 2004, 59:146-151.
29. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004, 61:300-308.
30. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
31. Looney S.W., el-Mallakh R.S. Meta-analysis of erythrocyte Na, K-ATPase activity in bipolar illness. Depress Anxiety 1997, 5:53-65.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193. 265-75.
33. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
34. Maede Y, Inaba M. (Na,K)-ATPase and Ouabain binding in reticulocytes from dogs with high K and low K erythrocytes and their changes during maturation 1985, 260. 3337-43.
35. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:463-493.
36. Manji H.K., Lenox R.H. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999, 46:1328-1351.
37. Naylor G.J., Smith A.H., Dick E.G., Dick D.A., McHarg A.M., Chambers C.A. Erythrocyte membrane cation carrier in manic-depressive psychosis. Psychol Med 1980, 10:521-525.
38. Noori S., Zafar H., Mahboob T. Biochemical effectiveness of cocoa powder on electrolytes homeostasis, liver and cardiac specific enzymes and renal function. Pak J Nutr 2009, 8:882-886.
39. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95.
40. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
41. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., Rao B.S. Erythrocyte membrane sodium-potassium adenosine triphosphatase activity in affective disorders. J Neural Transm Gen Sect 1992, 89:209-218.
42. Riegel R.E., Valvassori S.S., Elias G., Reus G.Z., Steckert A.V., de Souza B., et al. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009, 55:491-495.
43. Riegel R.E., Valvassori S.S., Moretti M., Ferreira C.L., Steckert A.V., de Souza B., et al. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain. Int J Dev Neurosci 2010, 28:233-237.
44. Rodrigo R., Prat H., Passalacqua W., Araya J., Guichard C., Bachler J.P. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007, 30:1159-1167.
45. Schafer M., Goodenough S., Moosmann B., Behl C. Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 2004, 1005:84-89.
46. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997, 54:9-13. discussion 14-15.
47. Shao L., Young L.T., Wang J.F. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005, 58:879-884.
48. Suzuki K. Basic neurochemistry 1981, Little Brown and Company, Boston.
49. Wang J.F., Bown C., Young L.T. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999, 55:521-527.
50. + pump via PKC-dependent activation of NADPH oxidase. Am J Physiol Cell Physiol 2009, 296:C693-700.
51. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 2003, 3:157-168.
52. Zarate C.A., Manji H.K. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 2009, 23:569-582.